ARCHIVES

Study Finds Up To 12 Percent Of Specimens Misdiagnosed

This article is from The Cancer Letter archive.

Vol. 28 No. 10 | October 28, 2005

Download PDF Visit The Full Archive

Related Articles

House Committee Investigates Marketing Practices Of Amgen And J&J For ESAs.

April 4, 2008

White House Estimates Automatic Budget Cuts Would Take 8.2 Percent From NCI, NIH and FDA

September 21, 2012

Natcher: Multiple Year Funding Would Not be Approved If Presented As Request For Reprogramming

March 22, 1985

NCI Cooperative Group, Cancer Center Trials Listed

September 28, 2007

Zaltrap Economics 101: The Pricing And Repricing of an Expensive Drug

November 16, 2012

Aranesp Study Finds No Difference In Survival Or Progression In Small-Cell Lung Cancer.

April 20, 2007